Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis.

Antimicrob Agents Chemother · 2026 · PMC12888891 · PMID 41493368

Europe PMC DOI

hedged sentence

1.0000

closest p · 20.0× alpha

1.0000

boldest claim

The sentences

did not reach statistical significanceP = 1.00not close (p > 0.1)

( 18 ) provided relevant data, observing no emergence of resistance in the M/V group compared with 20% in the C/A group among patients with recurrent CRE infections, a difference that did not reach statistical significance ( P = 1.00).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.